ESTRO 2024 - Abstract Book

S156

Brachytherapy - Breast

ESTRO 2024

Keywords: SCT, recurrence, HDR

References:

1. Hannoun-Levi JM et al. Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity Score- Matched Cohort Analysis of the GEC- ESTRO Breast Cancer Working Group Database. IJROB. 2020; S0360-3016(20)34722-2

2. Pinar-Sedeño MB, Calín-Lorca A, García- Cabrera L. Can breast cancer be reirradiated? Revista de Senología y Patología Mamaria, Volume 36, Supplement 1, 2023, 100497, ISSN 0214-1582.

1904

Digital Poster

VAPBI Multicatheter Brachytherapy offers Minimal Toxicity and Good Cosmesis.

Diana Correia, Pedro Fernandes, Sara Zorro, Alexandre Pereira, Lurdes Trigo

IPOPFG EPE, Brachytherapy, Porto, Portugal

Purpose/Objective:

Accelerated partial breast irradiation (APBI) delivered with high-dose-rate brachytherapy is a standard of care treatment typically delivered over 8 fractions. A multicentre Phase I e II trial endorsed by the GEC-ESTRO Breast Working Group recently demonstrated promising results using a shorter three fraction regimen (VAPBI). Here, we report our experience and outcomes for patients treated as per the cited regimen between May 2021 and July 2023.

Material/Methods:

This retrospective study was a single-institution analysis of 136 patients with pTis-2 pN0 breast carcinomas who received postoperative high dose rate multicatheter brachytherapy (MCB) in three fractions of 7.45 Gy/fr in 2 days. Patient selection was according to multicentre Phase I e II trial endorsed by the GEC-ESTRO Breast Working Group VAPBI. We evaluated acute toxicity (< 6 weeks), late toxicity (≥6 weeks) according to CTCAE v5, and cosmetic outcomes.

Results:

Median age was 68 (52 -83). Median follow-up was 13 months from completion of brachytherapy. No patient experienced grade 3 or higher acute toxicity. Regarding acute effects, dermatitis was present in 95.6% (erythema in the entrance and exit of tubes), infection in 0.7% (n=1) and breast pain in 1.5% (n=2). Cumulative late grade 1 and 2 toxicities were seen in 21.3% (n=29) and 4.4% (n=6) of patients, respectively. Patients presented G1-2 fibrosis, hyperpigmentation G1 and cellulitis in 18.3% (n=25), 6,6 % (n=9) and 1.5% (n=2), respectively. Cosmesis assessment following breast conserving surgery is an important measurable end point and is correlated with final